←
Annalisa Berzigotti1,510 posts
Annalisa Berzigotti avatar

Annalisa Berzigotti

@docberza

Hepatologist in Berne, with a passion for ultrasound, research, and human beings.

◷ Joined May 2011▧ 199 Photos and videos
Pierre Gholam avatar
⟳ Annalisa Berzigotti retweeted
Pierre Gholam@pgholam·Aug 28

Mushroom poisoning season is here In the midwest, it used to occur between 9/15 & 10/7 until the past 5 y but now happens earlier. We don’t do enough to warn the public about #amatoxin poisoning @FDA has expanded access to #silibinin so that’s a positive. #livertwitter

Post attachment
Mattias Mandorfer avatar
⟳ Annalisa Berzigotti retweeted
Mattias Mandorfer@MattiasMandorf1·Aug 20

Bavevo VIII is online @JHepatology 🙏 to my panel co-chair @docberza & panellists @JuanAbraldes @EltonDajti @mathiasjachs @VWSWong et al #LiverTwitter Time for another @EASLedu Talk Liver To Me Episode, @tom_marjot ?

It’s finally here‼️ 🎉 Baveno VIII has arrived — just in time for some good summer reading ☀️📖 Time to dive into the latest consensus on portal hypertension from @BavenoCoop Enjoy! 😉 🔗 journal-of-hepatology.eu/art…

Post attachment
Hong Jae Chon avatar
⟳ Annalisa Berzigotti retweeted
Hong Jae Chon@hongjaechon·Aug 4

🚨 Do cardiovascular or metabolic comorbidities impact STRIDE outcomes in uHCC? Post-hoc analysis of HIMALAYA in Liver Cancer! @ResearchKarger @LorenzaRimassa @StephenLChan1 👉 87% of patients had cardiovascular or metabolic comorbidities
👉 48-month OS with STRIDE: 28.0% (with cardiovascular) vs 21.7% (without)
👉 Long-term survival (≥36 mo): 28.2% (cardiovascular) and 22.6% (metabolic)
👉 No new safety signals — comorbidities should not preclude STRIDE! Full text: doi.org/10.1159/lic/admag001 @myESMO @EASLnews
#HCC #LiverCancer #Immunotherapy #Durvalumab #Tremelimumab Fig. 2. Proportion of long-term survivorsa in participants with comorbidities.

Post attachment
Journal of Hepatology avatar
⟳ Annalisa Berzigotti retweeted
Journal of Hepatology@JHepatology·Jun 17

🎉 We're proud to announce that our journal has achieved an Impact Factor of 40.1, now the highest in the field. Thank you to our editors, editorial board members, reviewers, authors, and publishing colleagues for making this possible. 👏

Post attachment
EASLnews avatar
⟳ Annalisa Berzigotti retweeted
EASLnews@EASLnews·May 22

🏛️ A historic moment for liver health. Yesterday at the 79th World Health Assembly, Member States adopted the resolution "Steatotic liver disease: a missing piece in the global noncommunicable disease response" — the first time liver disease has ever been formally recognised within the global NCD agenda. This is not a symbolic gesture. It is a mandate. For too long, steatotic liver disease — affecting an estimated 1.5 billion people worldwide — has been absent from national health plans, NCD financing frameworks, and government accountability mechanisms. That changes now. With this resolution, WHO Member States are called upon to: ✅ Integrate liver health into national NCD strategies ✅ Include liver health indicators in NCD monitoring frameworks ✅ Align health financing with integrated, prevention-centred care As Professor Debbie Shawcross, EASL Secretary General, said at our WHA79 side event yesterday: "The NCD community has fought for decades to put prevention at the centre of health systems. Liver disease has been a missing piece. With this resolution, we have a mandate. Now we need governments to make it count." The evidence is overwhelming. The EASL–Lancet Commission 2.0 estimates 780 preventable deaths per day and €55 billion in annual economic costs from liver disease in Europe alone. The vote has been cast. Now the real work begins — and EASL will be there every step of the way. 👉 Read our full press release: easl.eu/news/wha-side-event/ @DebbieShawcros1

Post attachment
Tom Hemming Karlsen avatar
⟳ Annalisa Berzigotti retweeted
Tom Hemming Karlsen@tomhemmingk·Apr 30

@TheLancet @EASLnews second Liver Commission report is online. What a tremendous team effort. A roadmap for health, far beyond that pertaining to liver disease. thelancet.com/journals/lance…

Thomas Reiberger avatar
⟳ Annalisa Berzigotti retweeted
Thomas Reiberger@ReibergerThomas·Apr 25

Alcohol abstinence can induce cirrhosis recompensation and thereby almost prevent liver-related mortality @BenediktHofer @salvatore_piano @PoseElisa et al @BavenoCoop in @JHepatology journal-of-hepatology.eu/art…